Urica Therapeutics is a clinical-stage biopharmaceutical company focused on developing pharmaceutical products for the treatment of gout and kidney diseases. The company utilizes a novel urate transporter (URAT1) inhibitor to reduce uric acid levels, addressing the complications associated with these conditions.
Funding
$2.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Gout, caused by elevated uric acid levels, leads to painful joint inflammation and the formation of tophi. Existing treatments often fail to adequately control uric acid levels, leaving many patients with poorly managed gout flares and increased risk of cardiovascular and kidney diseases.
Solution
Urica Therapeutics is developing Dotinurad, a selective urate transporter (URAT1) inhibitor, to lower blood uric acid levels by blocking uric acid reabsorption in the kidneys. Dotinurad is an oral, once-daily therapy. Clinical trials have demonstrated that Dotinurad is effective and well-tolerated, with a safety profile that avoids the cardiovascular risks associated with some existing treatments.
Target Audience
The primary target audience includes patients suffering from gout and hyperuricemia, as well as healthcare providers seeking safer and more effective treatment options.
Features
- Selective inhibition of URAT1 for targeted uric acid reduction
- Once-daily oral administration
- Demonstrated efficacy and tolerability in Phase 3 clinical trials
- Favorable safety profile compared to existing treatments like Febuxostat